TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18410408
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg once weekly plus acitretin 0.4 mg kg(‐1) daily
Study: 16338779
Drug: Butoconazole nitrate
Normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butoconazole nitrate 2% Site Release vaginal cream
Study: 16338779
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg tablets
Study: 12017904
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg, as a single dose, administered either 2 hours prior or immediately before the surgical procedure
Study: 10450625
Drug: Fluoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (30 or 60 mg daily)
Study: 25951410
Drug: Eating marshmallows
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating marshmallows (3 marshmallows three times daily)
Study: 23157581
Drug: Topiramate (3-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (3-25 mg/kg/day)
Study: 22195380
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) restorations with conditioners (GC Dentine Conditioner)
Study: 22195380
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) restorations without conditioners
Study: 18982338
Drug: NSAID (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (diclofenac 3 x 50 mg oral)
Study: 15991780
Drug: Nurse-delivered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-delivered intervention including tailored information, assessment of withdrawal, offer of nicotine replacement therapy, booklets, and a discharge letter.
Study: 12630068
Drug: Complete testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete testosterone suppression therapy
Study: 9527278
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) administered intravenously after dialysis
Study: 9527278
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) administered intravenously after dialysis
Study: 7885125
Drug: Cotrimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole)
Study: 2221512
Drug: IV metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV metoclopramide 10 mg
Study: 390339
Drug: Timolol administered
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol administered once a day
Study: 390339
Drug: Timolol administered
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol administered twice a day
Study: 390339
Drug: Timolol combined
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol combined with a diuretic
Study: 19232615
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (n=121)
Study: 15239792
Drug: 1.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/day molecular iodine for 6 months
Study: 15239792
Drug: 3.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/day molecular iodine for 6 months
Study: 15239792
Drug: 6.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg/day molecular iodine for 6 months
Study: 3285838
Drug: bromocriptine (2.5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine (2.5-30 mg/d)
Study: 24768981
Drug: Intravaginal misoprostol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal misoprostol, 400 μg, with 100 mL of 5% intravenous glucose (misoprostol arm)
Study: 24768981
Drug: Intravenous ketoprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketoprofen, 50 mg/mL, in 100 mL 5% glucose with intravaginal placebo (ketoprofen arm)
Study: 24768981
Drug: Vaginal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal placebo tablets, 100 mL 5% intravenous glucose (placebo arm)
Study: 21073062
Drug: 2PE preserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2PE preserved hepatitis B vaccine kept on the shelf <12 months (2PE New group)
Study: 21073062
Drug: 2PE preserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2PE preserved hepatitis B vaccine kept on the shelf >18 months (2PE Old group)
Study: 21073062
Drug: Thiomersal preserved
Normalized name: thiomersal
DrugBank: Thimerosal (DB11590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiomersal preserved hepatitis B vaccine [HBV(Thio) group]
Study: 21073062
Drug: 2PE preserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2PE preserved hepatitis B vaccine
Study: 17166386
Drug: Injection Yiyoutasai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Yiyoutasai (75 mg/m², every 3 weeks)
Study: 17166386
Drug: Injection Aisu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Aisu (75 mg/m², every 3 weeks)
Study: 2203467
Drug: Antibiotic plus
Normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic plus steroid
Study: 870388
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of dextran
Study: 870388
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral anticoagulation with cumarins
Study: 870388
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug prophylaxis)
Study: 27116918
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice a day)
Study: 27116918
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg twice a day)
Study: 27116918
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (21 mg per day with taper)
Study: 24725169
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin (two tablets of 0.2 mg once daily)
Study: 24725169
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin (one tablet of 0.2 mg and one tablet of placebo once daily)
Study: 22858560
Drug: Individualised sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised sensitivity elimination dose
Study: 22858560
Drug: Standardised 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised 15 min dose
Study: 19328636
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg St John's wort (SJW) active
Study: 17127698
Drug: Short induction
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short induction therapy with anti-thymoglobulin (ATG) and steroids for 4 days, followed by CellCept and tacrolimus
Study: 15894902
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg for 4 weeks followed by 10 mg for 4 weeks, n = 22)
Study: 15894902
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg for 8 weeks, n = 18)
Study: 15894902
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg for 1 week, 5.0 mg for 3 weeks and 10 mg for 4 weeks, n = 17)
Study: 10538640
Drug: Higher age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher age, breast-feeding, and knowledge of the recommendation to eat five or more servings of fruits and vegetables daily.
Study: 8878716
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate (MPA) 5 mg b.i.d.
Study: 8878716
Drug: dydrogesterone (DG)
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dydrogesterone (DG) 10 mg b.i.d.
Study: 1725022
Drug: Ramipril, 10
Normalized name: Ramipril, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril, 10 mg once daily for 4 weeks
Study: 31113725
Drug: Sitafloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitafloxacin (100 mg/day for 3–10 days)
Study: 31113725
Drug: Garenoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garenoxacin (400 mg/day for 3–10 days)
Study: 24844530
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) program in Manga format, delivered over six weeks with one lesson per week
Study: 20334707
Drug: 2.2 g
Normalized name: Vaporizer Safeguard 2.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g of marine n-3 PUFA daily for 12 weeks
Study: 20334707
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil daily for 12 weeks
Study: 18689157
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for hemophilia with inhibitors as per regional consensus and clinical guidelines.
Study: 15639064
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg / Ethinyl Estradiol 30 microg (DRSP/EE)
Study: 10233563
Drug: Oral desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desmopressin
Study: 8942381
Drug: Hyaluronidase (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase (25 IU/ml of mixture)
Study: 31336633
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (150 mL, 10.5 mmol nitrate)
Study: 31336633
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mL, 1 mmol nitrate)
Study: 23171659
Drug: Online disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online disease management intervention (n=193) including wirelessly uploaded glucometer readings, patient-specific reports, nutrition and exercise logs, insulin records, online messaging, nurse and dietitian support, and educational content.
Study: 20214224
Drug: BCAA granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA granules (14.22 g/day)
Study: 9302131
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 20 microg alprostadil alfadex (prostaglandin E1)
Study: 9302131
Drug: 30-minute intravenous
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute intravenous infusion of 20 microg alprostadil alfadex (prostaglandin E1)
Study: 8193494
Drug: Regular, aluminium‐adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular, aluminium‐adsorbed diphtheria‐tetanus vaccine
Study: 8193494
Drug: Non‐adsorbed diphtheria‐tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐adsorbed diphtheria‐tetanus vaccine
Study: 3332574
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg, 60 mg, or 90 mg once daily)
Study: 3332574
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol (80 mg, 160 mg, or 240 mg once daily)
Study: 27374465
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance therapy (375 mg/m² every 3 months for 2 years)
Study: 19338146
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) pre-treated group
Study: 19338146
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) post-treated group
Study: 16145898
Drug: Astragali injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragali injection
Study: 3015809
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g) given within 5 min of amitriptyline (75 mg) dose
Study: 3015809
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g followed by 12.5 g at 6-h intervals)
Study: 2142700
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dexamethasone
Study: 21077943
Drug: Orlistat plus
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat plus L‐carnitine
Study: 16963828
Drug: Subanesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic ketamine infusion (0.5 mg/kg/h)
Study: 9589227
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g b.i.d. for 12 weeks
Study: 9589227
Drug: Metformin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin at baseline dosage (1-2.5 g) for 12 weeks
Study: 3019375
Drug: Cilazapril 20
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 20 mg
Study: 780059
Drug: Indoramin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (125 mg to 200 mg daily)
Study: 28279119
Drug: Amnioinfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion with a 500-mL saline solution before the second ECV attempt
Study: 28449972
Drug: Paracetamol (prophylactic)
Normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (prophylactic)
Study: 28449972
Drug: Paracetamol (therapeutic)
Normalized name: Moisturel Therapeutic
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (therapeutic)
Study: 29690924
Drug: No paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No paracetamol
Study: 18501431
Drug: Ampicillin/sulbactam (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (9 g every 8h)
Study: 11099714
Drug: Piracetam 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 1600 mg t.i.d.
Study: 11099714
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 200 mg t.i.d.
Study: 15943850
Drug: lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 15 mg daily
Study: 9663835
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg daily
Study: 9663835
Drug: lansoprazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (both doses)
Study: 3786999
Drug: Dose-finding trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-finding trials
Study: 16628140
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg orally twice per day for 3 days)
Study: 16628140
Drug: Midazolam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2.5 mg and 1 mg intravenously)
Study: 1486974
Drug: Inhaled glucocorticosteroid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticosteroid, budesonide 400 micrograms b.i.d.
Study: 3721055
Drug: Intramuscular combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular combination of buprenorphine (0.3 mg)/naloxone (0.2 mg)
Study: 27169564
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg tablets
Study: 27169564
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg tablets
Study: 27169564
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg tablets
Study: 27169564
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg and 400 mg tablets
Study: 20113414
Drug: 8% lidocaine
Normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lidocaine spray
Study: 20113414
Drug: lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine patch
Study: 16816482
Drug: Active vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitamin D3 therapy
Study: 16816482
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Active vitamin D3 and bisphosphonates
Study: 9952390
Drug: Standard-dose ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ivermectin
Study: 9952390
Drug: High-dose ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ivermectin
Study: 2337571
Drug: 5% eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% eutectic mixture of lignocaine (100 mg) and prilocaine (100 mg) plus emulsifier (EMLA)
Study: 2337571
Drug: 10% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lignocaine spray (200 mg)
Study: 26001948
Drug: Zoledronate 5
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate 5 mg intravenous infusion
Study: 9432896
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural anesthesia with 20 mg of 1% lidocaine and maintained with 2% lidocaine through an epidural catheter (Group I)
Study: 9432896
Drug: Spinal plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal plain 20 mg of 0.5% bupivacaine (Group II)
Study: 9432896
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of plain 0.5% bupivacaine 3 ml (15 mg) with an incremental dose of 3 ml (15 mg) (Group III)
Study: 9432896
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of anesthetic (Group I)
Study: 9432896
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of anesthetic (Group II)
Study: 9432896
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of anesthetic (Group III)
Study: 7871065
Drug: Three IM
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 12-h intervals
Study: 7871065
Drug: Three IM
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 24-h intervals
Study: 7871065
Drug: Three IM
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 48-h intervals
Study: 7871065
Drug: Three IM
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 72-h intervals
Study: 7871065
Drug: Single IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IM morphine pretreatment (18 mg/70 kg) followed by naloxone challenge (10 mg/70 kg IM)
Study: 2878712
Drug: Bethanechol chloride
Normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bethanechol chloride (Urecholine) infused intracerebroventricularly with an Infusaid continuous infusion pump
Study: 27464461
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry powder (FDSP) 50 g daily for 1 week
Study: 24981605
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation performed at discharge by a hospital pharmacist with communication to the community pharmacist.
Study: 20863237
Drug: Desensitizer toothpaste
Normalized name: Fluorimax Sensitive Toothpaste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizer toothpaste and GaAlAs (diode) laser therapy
Study: 18794896
Drug: Ileal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal fat perfusion (3 g and 9 g safflower oil)
Study: 18794896
Drug: Ileal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal placebo infusion after fat-free liquid breakfast (treatment C)
Study: 12139807
Drug: NPTS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPTS with reticulated hyaluronic acid implant
Study: 11563408
Drug: Ganciclovir 2000
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 2000 mg tid taken within 30 minutes of a meal
Study: 11563408
Drug: Ganciclovir 2000
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 2000 mg tid taken on an empty stomach
Study: 2031393
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 40 mcg prostaglandin E1
Study: 7111875
Drug: Intranasal phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phenylephrine (0.25% solution)
Study: 30297499
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen (10 mg/kg every 6 hours until 24 hours after the first convulsion if fever >38.0°C)
Study: 27092831
Drug: MVA-BN-Filo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-Filo (1 × 10^8 median tissue culture infective dose)